Sarepta Therapeutics Inc (NASDAQ:SRPT)

24.26
Delayed Data
As of May 21
 -1.98 / -7.55%
Today’s Change
11.33
Today|||52-Week Range
35.45
+67.66%
Year-to-Date
Morning Market Losers
May 21 / Benzinga
Why I'm Buying Sarepta Therapeutics Stock
May 20 / MotleyFool.com
Today's Perilous Reversal Stock: Sarepta Therapeutics (SRPT)
May 21 / TheStreet.com
Watch These After-Hours Movers
May 20 / Benzinga
Benzinga's Top #PreMarket Losers
May 21 / Benzinga
Pre-Open Stock Movers 05/20: (SRPT) (ISR) (PBY) Higher; (LPTN) (ETSY) (ACHN) Lower (m...
May 20 / Investing Channel
Sarepta Explodes On Monster Volume Following Progress With FDA
May 20 / Benzinga
Benzinga's Top #PreMarket Gainers
May 20 / Benzinga
Sarepta to Finish Eteplirsen Regulatory Filing by Mid-15 - Analyst Blog
May 20 / Zacks.com
Sarepta Therapeutics (SRPT) Moving On Heavy Volume In The Pre-Market Hours
May 20 / TheStreet.com
Why Shares of Sarepta Therapeutics Skyrocketed Today
May 20 / MotleyFool.com
After-Hours Stock Movers 05/19: (SRPT) (DY) (CSC) Higher; (ETSY) (CISG) (NCLH) Lower ...
May 19 / Investing Channel
Sarepta Therapeutics (SRPT) Stock Soars Following Positive Meeting With FDA
May 20 / TheStreet.com
Market Wrap: Trading in Narrow Range Nets Mixed Results
May 19 / TheStreet.com
Benzinga's Volume Movers
May 20 / Benzinga
FDA Tells Sarepta Therapeutics: Come on Down With Your DMD Drug!
May 19 / TheStreet.com
Jim Cramer -- Regeneron Will Go Higher; Sarepta Is Rallying
May 20 / TheStreet.com
Forget Gilead Sciences, Inc. -- This Tiny Biotech Offers A Much Richer Opportunity
May 12 / MotleyFool.com
Morning Market Gainers
May 20 / Benzinga
Sarepta Posts Wider-than-Expected Loss, Eteplirsen in Focus - Analyst Blog
May 08 / Zacks.com

To view my watchlist

Not a member yet?

Sign up now for a free account